Thryv Therapeutics

Relentlessly pursuing treatments for cardiac conditions.

So people can live without limits.

Clinical Study

Now enrolling!

Wave II, a clinical study for people living with Long QT Syndrome Type 2 (LQTS2).

Learn More About Enrollment!

Our Focus:

Thryv Therapeutics is a clinical-stage biotech pioneering precision medicine approaches to treating genetic arrhythmia syndromes and acquired cardiometabolic diseases through potent and selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).

© 2026 Thryv Therapeutics, Inc. All rights reserved.

Follow our journey

We know considering a clinical study comes with questions. Our study team is here to help. 💚

Visit wavestudies.com/wave-2 to learn more.

Sharing some photos from our team’s time in Chicago at the Heart Rhythm Society Annual Meeting (April 23–26), one of the largest yearly gatherings of heart rhythm specialists in the world. ❤️

We loved spending time with the team at the @

Research is underway for LQTS.
If you or someone you know has been diagnosed with LQTS Type 2, the Wave II study is enrolling. Learn more at wavestudies.com/wave-2.

Participation is voluntary.
The Wave II study is sponsored by Thryv Therapeutics In

LQTS can be present even without symptoms.
That’s why awareness, genetic testing, and family screening matter.

#LongQTSyndrome #GeneticTesting #HeartHealth #RareDiseaseAwareness #PatientEducation

Knowing the facts can help support earlier recognition and care.

#LongQTSyndrome #HeartHealth #RareDisease #AwarenessMatters #PatientEducation

The Wave II clinical study is now enrolling to evaluate an investigational treatment option. Learn more at wavestudies.com/wave-2 💚

Participation is voluntary.
The Wave II study is sponsored by Thryv Therapeutics Inc.

We are now enrolling individuals living with Long QT Syndrome in the Wave II clinical study. 💚
What questions do you have about participating in research? Leave them in the comments below.

Did you know? 🌍 ~59 million people worldwide are living with atrial fibrillation (AF)—and prevalence continues to rise.

Last week in Amsterdam, our VP, Clinical Research, Alex Brkovic, joined the AF-B-STEP kickoff meeting on behalf of Thryv.

Today is Wear Red Day ❤️
At Thryv, we’re proud to stand together in red to raise awareness of the fight against cardiovascular disease in women – their number one killer. Together, we’re helping shine a light on women’s heart

myQTwave and Wave II are two distinct Long QT Syndrome studies with one shared purpose: advancing patient-centered care.

myQTwave helps us learn from people living with LQTS by tracking symptoms from home, while Wave II evaluates an investigational

Grateful today and every day for the incredible community that supports and strengthens our work in cardiac care. 💛

To the patients, families, advocates, clinicians, scientists, and partners who inspire us—thank you.
Wishing you all a warm, p

Three years ago, the world lost a bright little girl named Isla Hutton to Long QT Syndrome (LQT3). ❤️

At Thryv, Isla’s story — and the love and strength of her father, Dave Hutton (@thelongcutielegacy), who continues to advocate for fami

With FDA IND clearance and backing from leading life sciences investors, Thryv Therapeutics is advancing THRV-1268, our lead SGK1 inhibitor, into Phase 2/3 development for Long QT Syndrome. This combination of regulatory momentum and financing suppor

🚀 Driving science forward at #ESC2025.

Last week, Thryv Therapeutics showcased new preclinical data from a pressure overload (TAC) heart failure model, demonstrating that our lead SGK1 inhibitor, THRV-1268—alone and combined with Jardiance (e

📣 We’re headed to #ESCCongress this weekend! Thryv Therapeutics is proud to announce that we’ll be presenting compelling new preclinical results on our lead SGK1 inhibitor, THRV-1268, at the 2025 European Society of Cardiology Congress i

🔬 It all starts in the lab.
Delphine, Kayluz, and Julie are part of the team powering our research forward. From bench to breakthrough, they’re working behind the scenes to better understand SGK1 inhibition and its potential to transform the t

Breaking Barriers:

Press Releases

Thryv Therapeutics to Participate in UBS, RBC Capital Markets, and Jefferies Healthcare Conferences

Thryv Therapeutics to Participate in UBS, RBC Capital Markets, and Jefferies Healthcare Conferences

Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268

Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268

Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2

Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2

Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants

Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants

Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer

Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer

Thryv Therapeutics Launches myQTwave: A First-of-its-Kind Remote Study Enabling People with Long QT Syndrome to Join Cardiac Research

Thryv Therapeutics Launches myQTwave: A First-of-its-Kind Remote Study Enabling People with Long QT Syndrome to Join Cardiac Research

Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure

Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure

Thryv Therapeutics to Present at the 2025 American Heart Association Scientific Sessions in New Orleans, LA

Thryv Therapeutics to Present at the 2025 American Heart Association Scientific Sessions in New Orleans, LA

Thryv Therapeutics to Participate in Upcoming 2025 Healthcare Investor Conferences

Thryv Therapeutics to Participate in Upcoming 2025 Healthcare Investor Conferences

Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome

Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome

Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025

Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025

Thryv Therapeutics to Present at the 2025 European Society of Cardiology Congress in Madrid, Spain

Thryv Therapeutics to Present at the 2025 European Society of Cardiology Congress in Madrid, Spain

Thryv Therapeutics to Share Recent Clinical Results and Participate in Upcoming Healthcare Investor Conferences

Thryv Therapeutics to Share Recent Clinical Results and Participate in Upcoming Healthcare Investor Conferences

Thryv Therapeutics to Present at the 2025 Heart Rhythm Society Annual Meeting in San Diego, CA

Thryv Therapeutics to Present at the 2025 Heart Rhythm Society Annual Meeting in San Diego, CA

Thryv Therapeutics to Participate in the 2025 Piper Sandler Virtual Cardio Day

Thryv Therapeutics to Participate in the 2025 Piper Sandler Virtual Cardio Day

Thryv Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL

Thryv Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL

Thryv Therapeutics to Attend the 2025 J.P. Morgan Healthcare Conference in San Francisco

Thryv Therapeutics to Attend the 2025 J.P. Morgan Healthcare Conference in San Francisco

Thryv Therapeutics Announces the Appointment of Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical Officer

Thryv Therapeutics Announces the Appointment of Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical Officer

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025

Thryv Therapeutics Announces Participation in Four Major Upcoming Investor Conferences

Thryv Therapeutics Announces Participation in Four Major Upcoming Investor Conferences

Thryv Therapeutics to Sponsor and Participate in the 2024 International SADS Foundation Family Conference in Chicago

Thryv Therapeutics to Sponsor and Participate in the 2024 International SADS Foundation Family Conference in Chicago

Isla Hutton

Long QT Type 3

We gain momentum everyday in our relentless pursuit of a treatment for Long QT Syndrome — In memory of Isla.

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Together We Thryv

The enthusiasm of our investors is a reflection of breakthrough science, hard work and the dedication of our scientists, founders and collaborators.

Together we share a vision to transform the lives of people with life-threatening conditions.

Amplitude Ventures (Copy)

The Fonds de solidarité FTQ (Copy)

Lumira Ventures (Copy)

Amzak Health (Copy)

Alexandria Venture Investments (Copy)

adMare BioInnovations (Copy)